GlassScriptPhysician profile
Craig Ryan Grobman
NPI 1639119621
$20,799.05
in general payments reported to CMS, 2019-2025
60 companies · $7,613 in 2025
The $7,613 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,575 · 2020: $1,606 · 2021: $1,806 · 2022: $1,461 · 2023: $1,874 · 2024: $3,864 · 2025: $7,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,375 · Food and Beverage: $3,976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,375.00 |
| Food and Beverage | $3,976.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $10,239.87 | 2019-2025 | |
| Amgen INC. | $1,683.95 | 2019-2024 | Otezla, Repatha, Evenity |
| Abbvie INC. | $766.39 | 2020-2024 | |
| Amarin Pharma, INC. | $684.48 | 2019-2022 | |
| Allergan, INC. | $643.73 | 2019-2022 | |
| Lilly USA, LLC | $543.73 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $529.94 | 2019-2024 | Verquvo, Pneumovax 23, Vaxneuvance |
| Pfizer INC. | $484.49 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $450.27 | 2019-2024 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $436.23 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $393.06 | 2019-2024 | Wegovy |
| Intuity Medical INC | $377.71 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Astellas Pharma US INC | $321.95 | 2019-2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $291.31 | 2019-2024 | |
| Glaxosmithkline, LLC. | $258.36 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Grobman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.